What are the Implications of the Recently Announced Patent for Amgen’s Enbrel on the Biosimilar Market Amongst TNF-α Inhibitors? - On Demand

As part of our Biosimilars Advisory Service, Decision Resources is offering this exclusive webinar.

Date & Time
Recorded live on Thursday, December 15, 2011
10 a.m. ET, 4 p.m. CET

Click here to view the invite.

To learn how you can access the recorded playback of this live event, please fill out the following form and a representitive will contact you:

*First Name: *Last Name:  Title: *Company:  Phone: *Email Address:  Comments: *Agreement: No Yes I have read and agree to abide by the Decision Resources Terms of Use and Privacy Policy. *Required